

13 January 2025

Futura Medical plc
("Futura" or the "Company")

Remuneration of Non-Executive Directors and Total Voting Rights

Futura Medical plc (AIM: FUM) (the "Company"), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, announces the issue of 126,116 new ordinary shares of 0.2 pence each ("Ordinary Shares") in respect of the 2024 remuneration of its Non-Executive Directors .

Remuneration of Non-Executive Directors

In accordance with the terms of their service agreements, the Non-Executive Directors receive 25 per cent. of their remuneration in the form of Ordinary Shares. For 2024, these were issued at 27.10 pence per share, being the average closing mid-market price of the last 10 trading days of 2023 (as announced via RNS on 17 January 2024).

The 126,116 new Ordinary Shares shall rank pari passu with the existing issued Ordinary Shares of the Company and have been issued as follows:

Director	Number of Ordinary Shares issued for 2024 remuneration	Total number of ordinary shares held	Percentage of the Company's resulting issued share capital
Jeff Needham	55,600	83,561	0.01%
Andrew Unitt	30,221	68,717	0.01%
Roy Davis	40,295	40,295	0.01%

The shares element of the Non-Executive Directors' remuneration for 2025 will be awarded at 32.17 pence per Ordinary Share, being the average closing mid-market price of the last 10 trading days of 2024. The Non-Executive Directors will receive these shares in January 2026.

Total Voting Rights

Application has been made to the London Stock Exchange and it is anticipated that trading of the new Ordinary Shares will commence on AIM at 8:00am on 16 January 2025.

Immediately following the above issue, the Company will have 303,829,684 ordinary shares in issue, each carrying one voting right. Since the Company currently holds no shares in treasury, the total number of voting rights in the Company is therefore 303,829,684 and this figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Further details are contained within the notifications below, made in accordance with Article 19 of the EU Market Abuse Regulation 596/2014. Full details of the Non-Executive Directors' remuneration will be included in the Company's Annual Report & Accounts.

ENDS

Contacts:

Futura Medical plc	James Barder <i>Chief Executive Officer</i> Angela Hildreth <i>Finance Director and COO</i>	investor.relations@futuraomedical.com +44 (0)1483 685 670 www.futuraomedical.com
Panmure Liberum Nominated Adviser and Broker	Emma Earl, Will Goode, Mark Rogers (Corporate Finance) Rupert Dearden (Corporate Broking)	+44 (0)20 3100 2000
Stifel Nicolaus	Alan Selby	+44 (0)207 710 7600

Notes to Editors:

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon. Our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products.

Eroxon, Futura's clinically proven lead product, has been developed for the treatment of Erectile Dysfunction ("ED"). The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection in ten minutes, addresses significant unmet needs in the ED market.

ED impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40.

Futura has distribution partners in place in a number of major consumer markets including Haleon in the US, the largest market for ED in the world, and Cooper Consumer Health in Europe. Eroxon has been nominated for a number of healthcare industry awards and has won two to-date.

1	Details of the person discharging managerial responsibilities / person closely associated						
a)	Name	Jeff Needham					
2	Reason for the notification						
a)	Position/status	Director/ PDMR					
b)	Initial notification /Amendment	Initial notification					
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a)	Name	Futura Medical plc					
b)	LEI	21380053QLT46UNV2303					
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 0.2p each GB0033278473					
b)	Nature of the transaction	Issue of shares					
c)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>27.10 pence</td><td>55,600</td></tr></table>		Price(s)	Volume(s)	27.10 pence	55,600
Price(s)	Volume(s)						
27.10 pence	55,600						
d)	Aggregated information - Aggregated volume - Price	Not applicable					
e)	Date of the transaction	16 January 2025					
f)	Place of the transaction	Outside of trading venue					

1	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	Andrew Unitt
2	Reason for the notification	
a)	Position/status	Director/ PDMR
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	Futura Medical plc

b)	LEI	21380053QLT46UNV2303				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 0.2p each GB0033278473				
b)	Nature of the transaction	Issue of shares				
c)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>27.10 pence</td><td>30,221</td></tr></table>	Price(s)	Volume(s)	27.10 pence	30,221
Price(s)	Volume(s)					
27.10 pence	30,221					
d)	Aggregated information - Aggregated volume - Price	Not applicable				
e)	Date of the transaction	16 January 2025				
f)	Place of the transaction	Outside of trading venue				

1	Details of the person discharging managerial responsibilities / person closely associated						
a)	Name	Roy Davis					
2	Reason for the notification						
a)	Position/status	Director/ PDMR					
b)	Initial notification /Amendment	Initial notification					
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a)	Name	Futura Medical plc					
b)	LEI	21380053QLT46UNV2303					
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 0.2p each GB0033278473					
b)	Nature of the transaction	Issue of shares					
c)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>27.10 pence</td><td>40,295</td></tr></table>		Price(s)	Volume(s)	27.10 pence	40,295
Price(s)	Volume(s)						
27.10 pence	40,295						
d)	Aggregated information - Aggregated volume - Price	Not applicable					
e)	Date of the transaction	16 January 2025					
f)	Place of the transaction	Outside of trading venue					

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rs@seg.com or visit www.rs.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHFZGMMVGNGKZM